protegrin

protegrin

(prŏ′teg-rin)
Any of a class of cysteine-rich compounds, derived from mammalian peptides, that protect animals from a broad range of infections, including oral and periodontal diseases.
Mentioned in ?
References in periodicals archive ?
Huang, "Crystallization of antimicrobial pores in membranes: magainin and protegrin," Biophysical Journal, vol.
The duo studied the amino acid sequences and three-dimensional structures of over 500 antimicrobial peptides, and found the [gamma]-core structure in molecules as diverse as pea defensins, fruit fly drosomycin, pig protegrin, and human hepcidin.
This patent addresses the use of antimicrobial peptides, including Protegrin IB-367, for the treatment of oral mucositis, a severe and painful condition occurring in cancer patients receiving cancer therapies.
IntraBiotics' lead product candidates, Ramoplanin Oral for prevention of Vancomycin-Resistant Enterococci (VRE) bloodstream infections in cancer patients and Protegrin IB-367 Rinse for oral mucositis, are now in Phase III clinical studies.
has reported in two posters presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) results of studies on the company's novel antimicrobial peptide compound, Protegrin IB-367.
IntraBiotics has developed two new antibiotics, Ramoplanin Oral and Protegrin IB-367 Rinse, which are about to begin Phase III clinical trials.
Company Presents Positive Phase II Results of Protegrin IB-367 on Oral Mucositis; Separate Study Correlating Severity of Oral Mucositis And Health and Economic Outcomes
today announced the first ever presentation of their Phase II multinational study of Protegrin IB-367, an analog of a naturally occurring antibiotic originally purified from white blood cells.
5,994,306, entitled "Fine-Tuned Protegrins," for its anti-microbial agent, Protegrin IB-367, a synthetic protegrin analog that recently completed Phase II studies for the treatment of oral mucositis, a severe and painful condition occurring in cancer patients receiving myeloablative chemotherapy.
This capital infusion will provide us with additional funding necessary to begin each of our two Phase III studies with Protegrin and Ramoplanin," stated Kenneth J.
today announced the successful completion of the company's Phase II clinical study of Protegrin IB-367 Rinse for the prevention and treatment of oral mucositis, a severely debilitating ulcerative condition resulting from tissue damage caused by cancer therapies.
announced today the reacquisition of global rights to Protegrin IB-367, a topical antimicrobial, from Pharmacia & Upjohn, S.